Airway Defenses Against STAT3-Deficiency Related Lung Infections
Official title: Airway Epithelial Defense Mechanisms in Combating STAT3-Deficiency-Related Lung Infections
Funded at Florida International University · NIH-11376663 · Data updated 2026-11-12
This project looks at how the airways protect people with low STAT3 function from lung infections and what can be done to help prevent or treat them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida International University NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project start | June 10, 2026 |
| Project end | March 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $777,999 |
| NIH project number | 1R01HL180677-01A1 |
| Project ID | NIH-11376663 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with STAT3 deficiency or related conditions who are at heightened risk for recurrent lung infections.
✕Less likely to help
People without STAT3-related conditions or those not at risk for recurrent lung infections are unlikely to benefit from this research.
What this research studies
People with STAT3 deficiency often struggle with lung infections, including pneumonia and infections by Pseudomonas aeruginosa. The project focuses on how airway epithelial defenses work when STAT3 activity is reduced and how this affects susceptibility to bacterial infections. Researchers will study the mechanisms in airway cells and explore potential strategies to strengthen those defenses or use targeted therapies. The work could inform new approaches to prevent serious infections in patients with genetic STAT3 abnormalities.
Why it matters
Potential benefit: If successful, the research could lead to better prevention and treatment options for people with STAT3-related susceptibility to lung infections.
How similar studies have gone: Prior research has shown that STAT3 levels influence infection risk, and this study aims to translate those insights into airway-targeted strategies.
Where this research is happening
-
Florida International University
Miami, United States Active
Researchers
- Principal investigator: Di, Yuanpu Peter — Florida International University
- Study coordinator: Di, Yuanpu Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.